uniQure Prices Upsized $225M Public Offering at $45.50 Per Share
QURE has more than doubled off its 52-week low of $8.73.
Summary
uniQure priced an upsized public offering of 4.95 million ordinary shares at $45.50 each, raising approximately $225 million. This significantly increases the capital raise from the initially proposed $150 million offering announced on June 22nd. The funding provides substantial capital for the company's operations and pipeline, including the planned Q3 2026 BLA submission for its Huntington's disease gene therapy, AMT-130, which recently received positive FDA guidance. While dilutive, the upsized offering indicates strong market demand and strengthens the company's financial runway.
At the time of this announcement, QURE was trading at $48.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $8.73 to $71.50. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.